| scholarly article | Q13442814 |
| P356 | DOI | 10.1523/JNEUROSCI.1148-12.2012 |
| P8608 | Fatcat ID | release_fce6l4eakvfhbnv7q6uwzrlklm |
| P932 | PMC publication ID | 6621569 |
| P698 | PubMed publication ID | 23115180 |
| P5875 | ResearchGate publication ID | 232745837 |
| P50 | author | Huu Phuc Nguyen | Q62755583 |
| Laura E Clemens | Q84829115 | ||
| P2093 | author name string | David Howland | |
| Olaf Riess | |||
| Elisabeth Petrasch-Parwez | |||
| X William Yang | |||
| Bernd Pichler | |||
| Larry Park | |||
| Silke Metzger | |||
| Adriana Redensek | |||
| Xiaofeng Gu | |||
| Alexander P Osmand | |||
| Carsten Calaminus | |||
| Libo Yu-Taeger | |||
| P2860 | cites work | The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease | Q22306292 |
| A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. | Q27860836 | ||
| Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death | Q28287762 | ||
| Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain | Q29617982 | ||
| Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models | Q30483013 | ||
| Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells | Q30779186 | ||
| Subtle but progressive cognitive deficits in the female tgHD hemizygote rat as demonstrated by operant SILT performance. | Q30863991 | ||
| Quantitative relationships between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into huntington's disease molecular pathogenesis | Q30986761 | ||
| Formation and toxicity of soluble polyglutamine oligomers in living cells | Q30994681 | ||
| Differential loss of striatal projection neurons in Huntington disease | Q33637273 | ||
| Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression | Q33755845 | ||
| Correlation between the onset age of Huntington's disease and length of the trinucleotide repeat in IT-15. | Q34346913 | ||
| [Huntington's chorea] | Q66842211 | ||
| Trinucleotide repeat length instability and age of onset in Huntington's disease | Q34357407 | ||
| Mouse models of Huntington's disease | Q34502714 | ||
| The neostriatal mosaic: multiple levels of compartmental organization | Q35318347 | ||
| Neurobehavioral assessment in the information age. | Q35758824 | ||
| Imaging polyglutamine deposits in brain tissue | Q36626097 | ||
| Altered diffusion tensor imaging measurements in aged transgenic Huntington disease rats | Q36652239 | ||
| Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice | Q37072467 | ||
| Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington's disease. | Q37323312 | ||
| Species differences in pharmacokinetics and pharmacodynamics. | Q37702887 | ||
| Huntington's disease: can mice lead the way to treatment? | Q37840353 | ||
| Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease | Q40511251 | ||
| Mouse models of Huntington disease: variations on a theme. | Q42155772 | ||
| Sex differences in a transgenic rat model of Huntington's disease: decreased 17beta-estradiol levels correlate with reduced numbers of DARPP32+ neurons in males | Q42436584 | ||
| Early loss of neostriatal striosome neurons in Huntington's disease | Q42487671 | ||
| Cellular and subcellular localization of Huntingtin [corrected] aggregates in the brain of a rat transgenic for Huntington disease | Q42508306 | ||
| Transgenic rat model of Huntington's disease | Q44350467 | ||
| Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. | Q44400030 | ||
| Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders | Q44559402 | ||
| Patterns of cell and fiber vulnerability in the mesostriatal system of the mutant mouse weaver. I. Gradients and compartments | Q44680888 | ||
| Striosome-matrix pathology and motor deficits in the YAC128 mouse model of Huntington's disease | Q45290940 | ||
| Neuronal distribution of intranuclear inclusions in Huntington's disease with adult onset. | Q45296154 | ||
| Loss of matrix calcium-binding protein-containing neurons in Huntington's disease | Q45296972 | ||
| Neuropathological classification of Huntington's disease | Q45297167 | ||
| Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. | Q45297497 | ||
| Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington's disease | Q45298031 | ||
| Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease. | Q45298570 | ||
| Huntington aggregates may not predict neuronal death in Huntington's disease | Q45299493 | ||
| Intranuclear inclusions in subtypes of striatal neurons in Huntington's disease transgenic mice | Q45300021 | ||
| Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons | Q45300079 | ||
| Selective striatal neuron loss and alterations in behavior correlate with impaired striatal function in Huntington's disease transgenic rats | Q45300103 | ||
| Normal sensitivity to excitotoxicity in a transgenic Huntington's disease rat. | Q45300444 | ||
| Body weight is modulated by levels of full-length huntingtin | Q45300502 | ||
| Metabolic and type 1 cannabinoid receptor imaging of a transgenic rat model in the early phase of Huntington disease. | Q45302279 | ||
| Behavioral abnormalities precede neuropathological markers in rats transgenic for Huntington's disease. | Q45302545 | ||
| Light and electron microscopic characterization of the evolution of cellular pathology in YAC128 Huntington's disease transgenic mice | Q45303034 | ||
| Genotype specific age related changes in a transgenic rat model of Huntington's disease | Q45303655 | ||
| Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice. | Q45304186 | ||
| Microstructural changes observed with DKI in a transgenic Huntington rat model: evidence for abnormal neurodevelopment | Q45304299 | ||
| Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice | Q45306356 | ||
| Neostriatal projections from individual cortical fields conform to histochemically distinct striatal compartments in the rat. | Q48376749 | ||
| Huntington disease | Q48465200 | ||
| Homologous recombination based modification in Escherichia coli and germline transmission in transgenic mice of a bacterial artificial chromosome | Q48611307 | ||
| Neurochemical architecture of the human striatum | Q48656419 | ||
| Cytoarchitectonic heterogeneity of the primate neostriatum: subdivision into Island and Matrix cellular compartments | Q48967207 | ||
| A transgenic rat that develops Alzheimer's disease-like amyloid pathology, deficits in synaptic plasticity and cognitive impairment. | Q51956350 | ||
| Possibilities and limitations for high resolution small animal MRI on a clinical whole-body 3T scanner. | Q53193968 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 44 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Huntington's disease | Q190564 |
| P304 | page(s) | 15426-15438 | |
| P577 | publication date | 2012-10-01 | |
| P1433 | published in | Journal of Neuroscience | Q1709864 |
| P1476 | title | A novel BACHD transgenic rat exhibits characteristic neuropathological features of Huntington disease | |
| P478 | volume | 32 |
| Q47630786 | A novel transgenic rat model for spinocerebellar ataxia type 17 recapitulates neuropathological changes and supplies in vivo imaging biomarkers. |
| Q104495209 | Analysis of mutant and total huntingtin expression in Huntington's disease murine models |
| Q40061455 | Assessment of brain metabolite correlates of adeno-associated virus-mediated over-expression of human alpha-synuclein in cortical neurons by in vivo (1) H-MR spectroscopy at 9.4 T. |
| Q28534633 | Assessment of motor function, sensory motor gating and recognition memory in a novel BACHD transgenic rat model for huntington disease. |
| Q27311213 | Ataxin-2 regulates RGS8 translation in a new BAC-SCA2 transgenic mouse model |
| Q50055400 | BACHD rats expressing full-length mutant huntingtin exhibit differences in social behavior compared to wild-type littermates. |
| Q38139868 | Choosing an animal model for the study of Huntington's disease |
| Q58691859 | Cilostazol disrupts TLR-4, Akt/GSK-3β/CREB, and IL-6/JAK-2/STAT-3/SOCS-3 crosstalk in a rat model of Huntington's disease |
| Q40865908 | Coexistence of Gait Disturbances and Chorea in Experimental Huntington's Disease |
| Q26799722 | Developing stem cell therapies for juvenile and adult-onset Huntington's disease |
| Q35052612 | Development of an ELISA assay for the quantification of soluble huntingtin in human blood cells |
| Q35058593 | Early deficits in glycolysis are specific to striatal neurons from a rat model of huntington disease |
| Q54943751 | Environment-dependent striatal gene expression in the BACHD rat model for Huntington disease. |
| Q36300780 | Further investigation of phenotypes and confounding factors of progressive ratio performance and feeding behavior in the BACHD rat model of Huntington disease |
| Q47108384 | Genome-wide discovery of long intergenic noncoding RNAs and their epigenetic signatures in the rat. |
| Q27318766 | Huntington's disease cerebrospinal fluid seeds aggregation of mutant huntingtin |
| Q26830039 | Huntington's disease: the past, present, and future search for disease modifiers |
| Q39014966 | Mitochondrial membrane fluidity is consistently increased in different models of Huntington disease: restorative effects of olesoxime |
| Q38458943 | Mutant Huntingtin and Elusive Defects in Oxidative Metabolism and Mitochondrial Calcium Handling |
| Q45290815 | Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat. |
| Q38194510 | Pig models of neurodegenerative disorders: Utilization in cell replacement-based preclinical safety and efficacy studies. |
| Q38248688 | Preclinical models: needed in translation? A Pro/Con debate. |
| Q41979425 | Reduced motivation in the BACHD rat model of Huntington disease is dependent on the choice of food deprivation strategy |
| Q28534787 | Reversal learning and associative memory impairments in a BACHD rat model for Huntington disease |
| Q55159264 | Sexual behavior and testis morphology in the BACHD rat model. |
| Q97518971 | Site-specific ubiquitination of pathogenic huntingtin attenuates its deleterious effects |
| Q37530250 | Structural and molecular myelination deficits occur prior to neuronal loss in the YAC128 and BACHD models of Huntington disease |
| Q40507416 | Sustained mobilization of endogenous neural progenitors delays disease progression in a transgenic model of Huntington's disease |
| Q55121407 | The Alteration of Emotion Regulation Precedes the Deficits in Interval Timing in the BACHD Rat Model for Huntington Disease. |
| Q36238024 | The BACHD Rat Model of Huntington Disease Shows Signs of Fronto-Striatal Dysfunction in Two Operant Conditioning Tests of Short-Term Memory |
| Q45305623 | The BACHD Rat Model of Huntington Disease Shows Specific Deficits in a Test Battery of Motor Function |
| Q40402039 | The calpain-suppressing effects of olesoxime in Huntington's disease. |
| Q41967848 | The challenge in translating basic research discoveries to treatment of Huntington disease |
| Q28072937 | The chicken or the egg: mitochondrial dysfunction as a cause or consequence of toxicity in Huntington's disease |
| Q54262475 | Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic. |
Search more.